Late Breaking Clinical Research Session recordings now available.
2019 | HFSA

U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease

Practice News

The U.S. Food and Drug Administration (FDA) has approved VYNDAQEL® (tafamidis meglumine) and VYNDAMAXTM (tafamidis) for use in adults with cardiomyopathy due to transthyretin amyloidosis.  More information can be found here.